Safety aspects of omeprazole.
Omeprazole has been given to more than 2500 subjects, mostly in short-term studies for 2-4 weeks, but also to some patients for more than 2 years. An analysis of side-effects has so far not shown a specific pattern that could be attributed to the drug.
Sölvell
L
L
D000410:Alanine Transaminase / Q000097:blood; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D009853:Omeprazole; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000188:drug therapy
D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D003404:Creatinine; D000410:Alanine Transaminase; D009853:Omeprazole